162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use

Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection. Looking for more Headache & Migraine discussion? Check out the NeurologyLive ® Headache & Migraine clinical focus page . Episode Breakdown: 1:20 – Interpreting real world response after prior CGRP preventive failure 4:25 – Mechanistic reasons IV eptinezumab may drive early sustained benefit 6:25 – Clinical implications for earlier, more robust treatment sequencing 8:50 – Neurology News Network 11:20 – Integrating good days and Patient Global Impression scales into migraine trial design 15:30 – Future studies needed to advance precision migraine care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and

You can listen to 162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use online on Radio and Podcast. Open the player on this page to stream the available audio.

162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use is an episode from NeurologyLive Mind Moments.

This episode is 20:37 long.

This episode was published on Mar 6, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from NeurologyLive Mind Moments when more episodes are available from the podcast feed.